Strategic Partnerships Target pharma and biotech partners focused on oncology, leveraging ARIZ’s PRDM-targeting platform to accelerate preclinical assets toward animal studies and potential clinical collaborations.

Proof of Concept Highlight ARIZ's demonstrated selective killing of cancer cells with PRDM abnormalities to potential licensees and collaborators as a strong value proposition for joint development deals.

Funding & Milestones Capitalize on recent angel funding and small grant-style investments to validate milestones; propose co-development or milestone-based partnerships to de-risk early-stage programs for larger financiers.

Clinical Pathway Position ARIZ's pipeline progression toward animal models as a stepping stone to IND-enabling studies, offering pharma partners opportunities to co-fund translational research and later-stage clinical planning.

Market Readiness Emphasize the unmet need for cancers with PRDM deregulation and the potential to reduce adverse effects; align messaging with larger CROs and contract development providers seeking differentiated oncology platforms.